4.5 Review

NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms

Journal

BLOOD REVIEWS
Volume 31, Issue 2, Pages 77-92

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2016.10.001

Keywords

NF-kappa B pathway; B-cell lymphoma; Apoptosis; MiRNA; Tumor microenvironment; EBV

Categories

Funding

  1. National Cancer Institute/National Institutes of Health [R01CA138688, 1RC1CA146299, P50CA136411, P50CA142509]
  2. hematology/oncology scholarship award
  3. University of Texas MD Anderson Cancer Center Lymphoma Moonshot Program
  4. Institutional Research and Development Fund
  5. Institutional Research Grant Award
  6. MD Anderson Cancer Center Lymphoma Specialized Programs on Research Excellence (SPORE) Research Development Program Award
  7. MD Anderson Cancer Center Myeloma SPORE Research Development Program Award
  8. Gunderson Lutheran Medical Foundation Award
  9. MD Anderson's Cancer Center Support Grant [CA016672]
  10. University Cancer Foundation via the Sister Institution Network Fund at The University of Texas MD Anderson Cancer Center

Ask authors/readers for more resources

The NF-kappa B pathway, a critical regulator of apoptosis, plays a key role in many normal cellular functions. Genetic alterations and other mechanisms leading to constitutive activation of the NF-kappa B pathway contribute to cancer development, progression and therapy resistance by activation of downstream anti-apoptotic pathways, unfavorable microenvironment interactions, and gene dysregulation. Not surprisingly, given its importance to normal and cancer cell function, the NF-kappa B pathway has emerged as a target for therapy. In the review, we present the physiologic role of the NF-kappa B pathway and recent advances in better understanding of the pathologic roles of the NF-kappa B pathway in major types of lymphoid neoplasms. We also provide an update of clinical trials that use NF-kappa B pathway inhibitors. These trials are exploring the clinical efficiency of combining NF-kappa B pathway inhibitors with various agents that target diverse mechanisms of action with the goal being to optimize novel therapeutic opportunities for targeting oncogenic pathways to eradicate cancer cells. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available